ALD

Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update

Retrieved on: 
Wednesday, February 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, NASH, Sumitomo Pharma, Biomarker, CFO, ALD, ODD, European Commission, Edema, Acceleration, ADPKD, Prescription, Safety, Human, Patient, Clinical trial, Workforce, Fibrosis, Autosomal dominant polycystic kidney disease, Merck Serono, Serono, Food, Adrenoleukodystrophy, Histology, EUR, POC, IRIS, Merck, IPF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Male, USD, VLCFA, Plasma, Fatty liver disease, Disease, FDA, Magnetic resonance imaging, Pioglitazone, TZD, JPY, Imeglimin, DSM-IV codes, COVID-19, AMN, Pharmacokinetics, Pharmaceutical industry, Security (finance), Management, Sumitomo Group, Euronext

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We are very pleased with the most recent figures of TWYMEEG sales in Japan.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We are very pleased with the most recent figures of TWYMEEG sales in Japan.
  • For the Sumitomo fiscal year 2023 (ending March 31, 2024), as a conservative assumption Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • In Q4 2022, Poxel initiated a corporate savings plan which includes a significant workforce reduction.
  • Full-Year Cash and Revenue ended December 31, 2022
    As of December 31, 2022, total cash and cash equivalents were EUR 13,1 million (USD 14 million)3, as compared to EUR 32,3 million at December 31, 2021 and EUR 17.1 million at September 30, 2022.

Azbil Launches New Sapphire Capacitance Diaphragm Gauges with MEMS Processing Technology to Enhance Resistance to Deposition

Retrieved on: 
Thursday, February 2, 2023
Engineering, Semiconductor, Technology, Manufacturing, Other Technology, Other Manufacturing, Hardware, Growth, Multimedia, ALD, Vacuum, MEMS, Gas, Corporation, Diaphragm, SPG, V8, Camera, Borosilicate glass

Azbil Corporation (TOKYO:6845) announced the availability as of January 25 of its model V8 sapphire capacitance diaphragm gauges, which employ MEMS*1 processing technology to enhance resistance to deposition*2 on the sensor.

Key Points: 
  • Azbil Corporation (TOKYO:6845) announced the availability as of January 25 of its model V8 sapphire capacitance diaphragm gauges, which employ MEMS*1 processing technology to enhance resistance to deposition*2 on the sensor.
  • Such a shift causes operators of film deposition and etching equipment to adjust the vacuum gauge more frequently, interfering with manufacturing plans.
  • In seeking a better solution, Azbil has thoroughly redesigned its current sapphire capacitance diaphragm gauge and released the model V8, which has a sensor with a new structure, flow path, etc.
  • MEMS technology is used to make the sensor chip’s surface uneven, helping to break up film deposited on the sensor diaphragm.

Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy

Retrieved on: 
Wednesday, January 25, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, NASH, ALD, ODD, Drug, European Commission, Civil service commission, AMPK, Patient, Committee, COMP, EMA, Thiazolidinedione, Food, Adrenoleukodystrophy, European Medicines Agency, POC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Fatty liver disease, Adenosine, Pioglitazone, DSM-IV codes, AMN, European, Pharmaceutical industry, EU, Euronext

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD).

Key Points: 
  • POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD).
  • The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
  • The U.S. Food and Drug Administration has previously granted ODD and Fast Track Designation to both PXL770 and PXL065 for the treatment of ALD.
  • ODD in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP).

Forge Nano Unveils New Brand Identity and Introduces Atomic Armor™, an Essential Technology to Revolutionize the Battery Market

Retrieved on: 
Friday, February 17, 2023
Engineering, Bacteria, Science, Nano, Brabantsche Compagnie, ALD, Atomic layer deposition, Safety, Atomic, Create

At the core of this new brand identity, Forge Nano has also introduced Atomic Armor™, the company's proprietary nanocoating technology that enables atomic level engineering and nanoscale surface engineering to build better materials.

Key Points: 
  • At the core of this new brand identity, Forge Nano has also introduced Atomic Armor™, the company's proprietary nanocoating technology that enables atomic level engineering and nanoscale surface engineering to build better materials.
  • Forge Nano has built a portfolio of equipment and tools to apply Atomic Armor™ onto nearly any surface and form factor.
  • With Atomic Armor™, Forge Nano is the only company delivering this innovative technology at commercial scale.
  • Elements of Forge Nano's new brand identity include:
    New Company and Brand Logos: The updated Forge Nano logo incorporates fresh, electric colors that reflect the company's bold vision for the future.

ALD: ALD reports full year 2022 results

Retrieved on: 
Sunday, February 12, 2023
Flex, Electric vehicle, Asset, Partnership, Sabadell, Depreciation, Société Générale, Carbon footprint, EVS, ACPR, Service, III, AMF, Growth, Kia, Sale, Acquisition, Consortium, S&P Global, Bank, Dec, UCS, European Commission, DNB, EUR, CO2, Return, BBB, LeasePlan, ECB, EGM, VS, NET, Mass meeting, EV, Credit, ALD, Exercise, Risk, History, Film, Jet fuel, Real estate, Renewable energy, Animal, Financial services, Risk management, Security (finance), Airline, Renting, Lease

On 8 February 2023, Tim Albertsen, ALD CEO, commenting on the full year 2022 Group Results, stated: “In spite of a deteriorating geopolitical and macroeconomic environment, with continued disruptions of supply chains, ALD recorded a landmark year.

Key Points: 
  • On 8 February 2023, Tim Albertsen, ALD CEO, commenting on the full year 2022 Group Results, stated: “In spite of a deteriorating geopolitical and macroeconomic environment, with continued disruptions of supply chains, ALD recorded a landmark year.
  • Since the announcement of its intention to acquire LeasePlan in January 2022, ALD reached a few number of key milestones towards closing.
  • In December 2022, ALD successfully completed its EUR 1.2 billion rights issue, thus securing the financing of the cash component of the transaction price.
  • ALD registered record financial results in 2022, driven by the strong increase in margins and exceptionally high UCS results, which more than offset the LeasePlan acquisition-related costs incurred in 2022.

Outlook on the Deposition Equipment Global Market to 2027 - Featuring Applied Materials, Tokyo Electron, Lam Research, ASM International and Veeco Instruments Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023
Other Manufacturing, Manufacturing, Electroplating, ALD, Electronics, Applied Materials, Data storage, PECVD, Growth, Plasma, PVD, Device file, Solar energy, MOCVD, ASM International, Sputtering, Environment, LPCVD, Renewable energy

In 2021, PECVD segment lead the deposition equipment market and is expected to be the highest growing segment in the coming years.

Key Points: 
  • In 2021, PECVD segment lead the deposition equipment market and is expected to be the highest growing segment in the coming years.
  • By Application: In the report, the global deposition equipment market is divided into six segments based on the application: Semiconductor & Microelectronics, Solar Products, Data Storage, Medical Equipment, Cutting Tools, and Other.
  • By Region: The global deposition equipment market can be divided into four regions: Asia Pacific, North America, Europe, and Rest of the World.
  • The key players of the global deposition equipment market are

Global Deposition Equipment Market Report to 2027: Rising Silicon Wafer Demand and Escalating Use of Advanced Medical Equipment Drives Growth

Retrieved on: 
Tuesday, January 3, 2023
Internet, ASM International, IOT, US, Urbanization, AI, Semiconductor, Growth, COVID-19, Nature, Robotics, EVS, PVD, Collection, LED, ALD, Artificial intelligence, Electronics, Investment, Maintenance, Silicon, Applied Materials, 3D printing, Consumer electronics, Animal

Some of the major reasons why companies are using deposition equipment are the growth in consumer electronics industry, rise in automotive industry, escalating use of advanced medical equipment, increasing demand for environmentally friendly coating processes, rising silicon wafer demand, etc.

Key Points: 
  • Some of the major reasons why companies are using deposition equipment are the growth in consumer electronics industry, rise in automotive industry, escalating use of advanced medical equipment, increasing demand for environmentally friendly coating processes, rising silicon wafer demand, etc.
  • Global Deposition Equipment Market Dynamics:
    Growth Drivers: One of the most important factors impacting deposition equipment market dynamics is the growth in consumer electronics industry.
  • The surge in demand for consumer electronics has directly impacted the growth in deposition equipment market, especially due to growth in demand for semiconductor market, which is a major end-user of deposition equipment market.
  • Therefore, the high cost associated with deposition equipment manufacturing makes it a challenge for the deposition equipment market.

Lightwave Logic Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Monday, December 19, 2022
Movement, Acquisition, Conference, Telecommunication, PIC, Internet, ETH Zurich, Technology transfer, ALD, Temperature, ECOC, Marketing, Karlsruhe Institute of Technology, Die (integrated circuit), Engineering, IPSR, Photonic integrated circuit, Doctor of Philosophy, Polymer, LightWave 3D, Kurdistan, European Conference on Radar in Meteorology and Hydrology, International conference on Physics of Light–Matter Coupling in Nanostructures, Communes of Burundi, Form 10-K, EO, Risk, Photochemistry, Patent, Percussion section, Russell, Logic, Silicon, Computer data storage, Video game console, 3D printing

We continued working with our packaging partner in 2022 to package our polymer modulators into traditional gold-boxes for reliability testing and evaluation.

Key Points: 
  • We continued working with our packaging partner in 2022 to package our polymer modulators into traditional gold-boxes for reliability testing and evaluation.
  • Looking ahead to 2023, we see a significant cadence of likely catalysts to drive forward long-term shareholder value creation.
  • Lightwave Logic, Inc. (NASDAQ: LWLG) is developing a platform leveraging its proprietary engineered electro-optic (EO) polymers to transmit data at higher speeds with less power.
  • The company's high-activity and high-stability organic polymers allow Lightwave Logic to create next-generation photonic EO devices, which convert data from electrical signals into optical signals, for applications in data communications and telecommunications markets.

ALD announces General Management committee change

Retrieved on: 
Sunday, December 18, 2022
Acquisition, Executive, Regulatory News Service, ALD, Compartment (heraldry), Heart, Sorbonne University, ALD Automotive, ISIN, Operation, LeasePlan, Growth, Ticker, Rale, SME, International trade, Paris Dauphine University, Security (finance), Management, Euronext Paris

ALD today announces that Gilles Bellemère has decided to step down from his position as Deputy Chief Executive Officer of ALD, effective 31 December 2022, in order to focus on his role as Chief Executive Officer of ALD Automotive France, the Group’s largest subsidiary, in addition to the direct supervision of ALD Automotive in Morocco and Algeria.

Key Points: 
  • ALD today announces that Gilles Bellemère has decided to step down from his position as Deputy Chief Executive Officer of ALD, effective 31 December 2022, in order to focus on his role as Chief Executive Officer of ALD Automotive France, the Group’s largest subsidiary, in addition to the direct supervision of ALD Automotive in Morocco and Algeria.
  • This decision to adapt the organisation of the Group’s General Management team was approved by ALD’s Board of Directors.
  • In addition to his role as Deputy Chief Executive Officer of ALD, Gilles Bellemère, was appointed Chief Executive Officer of ALD Automotive France in 2019.
  • ALD is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: ALD).

Amber Salzman, Ph.D., CEO of Epic Bio, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D

Retrieved on: 
Wednesday, December 7, 2022
Research, Women, Genetics, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Gene expression, Biotechnology, Therapy, AAV, Culture, A1AD, GEMS, Woman, DCAS, Amber, Stop, Patient, Epic, DNA, Research, Disease, ALD, News, FSHD, Horizons Ventures, CRISPR, DNA-binding protein, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Vaccine

She will additionally be featured in Endpoints Women in Biopharma 2022 special report.

Key Points: 
  • She will additionally be featured in Endpoints Women in Biopharma 2022 special report.
  • I am honored to be selected as one of Endpoints influential women blazing trails in biopharma, but my success would not have been possible without the Epic Bio team and the many people who supported and mentored me through my journey.
  • In addition, we have built a culture of diversity and inclusivity at Epic that enhances our ability to innovate.
  • Each year, Endpoints News selects 20 women in biotech to be honored as trailblazers in biopharma R&D.